Crystalline Salt Forms of Compound 1 for Stable T-Type Channel Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need to develop and characterize different salts and crystalline forms of N-((1-(2-(tert-butylamino)-2-oxoethyl)piperidin-4-yl)methyl)-3-chloro-5-fluorobenzamide (Compound 1) to address aberrant T-type calcium channel function associated with diseases such as psychiatric disorders, pain, tremor, and epilepsy, as existing formulations may lack stability and efficacy.
Innovation Solution
The development of various crystalline forms of Compound 1, including acetate, adipate, ascorbate, and other salts, characterized by specific X-ray powder diffraction patterns, to enhance stability and therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing formulations of Compound 1 are used, then the basic therapeutic function is provided, but stability and efficacy are insufficient
Solution Approach 1:
The patent applies parameter changes by transforming Compound 1 into different salt forms (sulfonate salts, carboxylate salts, phosphate salts, etc.), which are characterized by distinct X-ray powder diffraction patterns. This chemical form transformation improves stability and efficacy while maintaining the core therapeutic function of T-type calcium channel modulation.
Solution Approach 2:
The patent creates composite crystalline structures by combining Compound 1 with various counterions to form stable salt complexes. These composite materials exhibit enhanced stability and efficacy compared to the parent compound alone, as evidenced by their unique and reproducible diffraction patterns that confirm their distinct crystalline nature.
2Reliability
If multiple salt forms are developed, then stability and efficacy are improved, but characterization complexity increases
Solution Approach 1:
The patent replaces complex chemical and physical characterization methods with X-ray powder diffraction analysis as the primary identification tool. Each salt form is uniquely identified by its diffraction pattern, providing a simple, reproducible, and unambiguous method to distinguish between different crystalline forms without requiring complex analytical procedures.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The crystalline forms of Compound 1 provide improved stability and therapeutic benefits for treating neurological and psychiatric disorders, including essential tremor and epilepsy, by selectively modulating T-type calcium channels.
Implementation Method 1
characterized by an X-ray powder diffraction pattern (XRPD pattern) that includes at least one peak at the diffraction angle (° 2θ) selected from the group of peaks listed in Table 1
Data Source
AI summary
Described herein, in part, are crystalline and salt forms of N-((1-(2-(tert-butylamino)-2-oxoethyl)piperidin-4-yl)methyl)-3-chloro-5-fluorobenzamide useful for preventing and/or treating a disease or condition relating to aberrant function of a T-type calcium channel, such as epilepsy and epilepsy syndromes (e.g., absence seizures, juvenile myoclonic epilepsy, or a genetic epilepsy), tremor (e.g., essential tremor), and psychiatric disorder (e.g., mood disorders (e.g., major depressive disorder)).